investor focus much shift medicar part
busi pbm segment new benefit hcb segment
well numer new line item provid three primari segment
overhaul model follow first post-aetna deal report period
relat initi guidanc come away feel least concern
relat pbm segment despit pbm greatest amount perceiv
risk investor head management still highlight pbm minimum
guarante risk price hit bln renew pbm custom contract
news still net dilut net impact still bad
pbm guidanc low single-digit ebit declin given disclos
custom contract loss off-set less exposur pbm minimum rebat
guarante vs greater contribut receiv lot investor
interest pbm assumpt believ fulli load profit less
onboard expens off-set hit carri
thu project ebit growth pbm segment see pg
retail hcb segment relat expect retail ebit declin
seem omnicar ocr asset acquir year ago may account
total declin ocr may wit ebit declin isol
core retail op encourag expect retail script growth
combin trend expect ocr improv project rebound
retail ebit growth follow expect ebit declin
hcb segment incur invest spend disclos management
expect ebit growth improv due medicar
membership growth leverag togeth lower ep
trim price-to-earnings reflect greater challeng pharma suppli
channel off-set continu favor outlook medicar growth pt reduc
base price-to-earnings new ep estim
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight combin aetna set
compani path off-set slower-growth
retail pbm busi fast-grow aetna
busi expect acceler growth
establish key healthcar partner
upsid case see better expect synergi
cross sell product improv medic loss
ratio combin retail pbm
upsid case see higher multipl
downsid case see slower expect
synergi aetna transact misstep
handl insur portion busi
coupl slower growth pbm/retail busi
lead multipl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
 guidanc outlookenterpris mlnenterpris segment outlook retail milretail/ltc ebit servic servic lsd benefit outlook year end medic mlnadjust /- bpshcb commerci medic /- bpsother itemsinterest mlntax changegaap mlnnet mlnincrement invest mlncash retail/ltcstrong script growth pharmacyannu tax reform invest ltccontribut half segment contactioncontinu reimburs pressuref expect drive marginnot pbmprice compress worsen low brand inflationbenefit sell season modestanthem strong headwind due acceler timelineanthem revenu record net basisaetna mail order specialti pbmnote deal synergi benefit hcb mostincrement invest acceler growthsuspens hif impact certain op ratioscertain one-tim benefit repeat segment shift invesmtnet hif op incom growmodestli enterpriseseason result resembl pbm see greatest y/i deterior op incom greatest lowest barclay
 annual segment analysi mln
segment product revenueactualprojectedprojectedprojectedgross gross oper amort oper oper chang oper oper barclay
 annual incom statement invest product sold ex one-tim expens ex one-tim addback expens pre-tax rate minor interest/earn net ep fulli combin co ep dilut share line growth expens ex one-tim pre-tax net per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
